<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03996486</url>
  </required_header>
  <id_info>
    <org_study_id>20414</org_study_id>
    <secondary_id>2018-004566-34</secondary_id>
    <nct_id>NCT03996486</nct_id>
  </id_info>
  <brief_title>Study to Test the Safety of an Investigational Drug Given Repeatedly to Adult Men With Severe Hemophilia</brief_title>
  <official_title>A Multicenter, Non-randomized, Open-label, Multiple Dose Escalation Study to Evaluate the Safety and Tolerability of Subcutaneous BAY1093884 in Males With Severe Hemophilia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety of a test drug to treat hemophilia in
      adult men.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective is to assess the safety of multiple doses of BAY1093884.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Company decision
  </why_stopped>
  <start_date type="Anticipated">October 28, 2019</start_date>
  <completion_date type="Anticipated">July 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 29, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of drug-related adverse events</measure>
    <time_frame>Up to 3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of drug-related serious adverse events</measure>
    <time_frame>Up to 3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of adverse events of special interest</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>Adverse events of special interest comprise thromboembolic and thrombotic microangiopathy events, and hypersensitivity reactions.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Hemophilia</condition>
  <arm_group>
    <arm_group_label>Hemophilia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation starting with 200 mg of BAY1093884</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAY1093884</intervention_name>
    <description>Drug administered via subcutaneous injections once weekly for 6 weeks (= 6 doses)</description>
    <arm_group_label>Hemophilia</arm_group_label>
    <other_name>Human monoclonal immunoglobulin G2 antibody blocking the endogenous tissue factor pathway inhibitor (TFPI)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants with hemophilia A and FVIII activity &lt;1% or hemophilia B with FIX
             activity &lt;2%

          -  Participants must be currently without inhibitors or with low titer inhibitors
             (inhibitor titer &lt; 5 Bethesda units) who are receiving current on demand treatment
             with any FVIII or FIX (recombinant or plasma-derived; modified or unmodified)

        Exclusion Criteria:

          -  History or at risk of developing diseases related to venous thromboembolic events
             (e.g., pulmonary embolism, deep vein thrombosis or thrombophlebitis)

          -  History of any other clinically relevant coagulation disorder (particularly
             disseminated intravascular coagulopathy or combined FVIII/Factor V deficiency) or
             platelet disorder

          -  History or at risk of developing cardiac, coronary and/or arterial peripheral
             atherosclerotic disease and/or arterial thromboembolic events, particularly myocardial
             infarction, cerebrovascular accident, stroke, transient ischemic attack, congestive
             heart failure, angina pectoris, treatment for angina pectoris or uncontrolled
             hypertension

          -  History or at risk for thrombotic microangiopathy
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Ukraine</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>June 21, 2019</study_first_submitted>
  <study_first_submitted_qc>June 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 24, 2019</study_first_posted>
  <last_update_submitted>October 21, 2019</last_update_submitted>
  <last_update_submitted_qc>October 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Coagulation Factor VIII (FVIII)</keyword>
  <keyword>Coagulation Factor IX (FIX)</keyword>
  <keyword>Anti-tissue factor pathway inhibitor (aTFPI)</keyword>
  <keyword>Human monoclonal immunoglobulin G2 antibody</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lipoprotein-associated coagulation inhibitor</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Immunoglobulin G</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Myeloma Proteins</mesh_term>
    <mesh_term>Paraproteins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Availability of this study's data will be determined according to Bayer's commitment to the EFPIA/PhRMA &quot;Principles for responsible clinical trial data sharing&quot;. This pertains to scope, timepoint and process of data access.
As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014.
Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

